J&J slides as device margins droop, drug sales seen falling financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
(Bloomberg) Johnson & Johnson shares tumbled after the company said profit margins in its medical device and technology unit fell last quarter and drug sales will be lower in the second half of the year than the first.Most Read from BloombergChina Weighs Stock Market Rescue Package Backed by $278 BillionNetflix Pays $5 Billion for ‘Raw’ in Bet on Live EventsAn Isolated Israel Doubles Down on War in Gaza — At All CostsIndia Tops Hong Kong as World’s Fourth-Largest Stock MarketHong Kong Stocks
J&J touts progress on new launches as Stelara cliff nears fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
In its 2022 annual report, New Brunswick health care giant Johnson & Johnson announced its medical devices division would be rebranded as Johnson & Johnson MedTech.
Big jumps in sales of prescription drugs and medical devices helped Johnson & Johnson boost its first-quarter profit nearly 7 per cent, blowing past Wall Street forecasts. The health care giant on Tuesday raised and narrowed its financial forecasts for 2021, and its shares jumped more than 2 per cent in midday trading. The one weak spot was a small drop in consumer health sales, which saw a surge in 2020 s first quarter, when nervous consumers stocked up on over-the-counter medicines and hygiene products as the coronavirus pandemic set in and lockdowns began. Meanwhile, Johnson & Johnson last week paused administration of its COVID-19 vaccine, due to worries over roughly one in a million vaccine recipients developing unusual blood clots along with low blood levels. One of them died.